CO2018000652A2 - Anticuerpo anti-epha4 - Google Patents
Anticuerpo anti-epha4Info
- Publication number
- CO2018000652A2 CO2018000652A2 CONC2018/0000652A CO2018000652A CO2018000652A2 CO 2018000652 A2 CO2018000652 A2 CO 2018000652A2 CO 2018000652 A CO2018000652 A CO 2018000652A CO 2018000652 A2 CO2018000652 A2 CO 2018000652A2
- Authority
- CO
- Colombia
- Prior art keywords
- epha4
- antibody
- binding
- mouse anti
- epha4 antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se pretende proporcionar un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 del mismo que sea capaz de unirse a EphA4 e inhibir la unión entre EphA4 y su ligando, y una composición farmacéutica que comprende el anticuerpo anti-EphA4 o el fragmento de unión a EphA4 del mismo como un ingrediente activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión por EphA4, y se identificaron las secuencias de regiones determinantes de complementariedad (CDRs) del anticuerpo anti-EphA4 de ratón. Esto permitió la preparación de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo anti-EphA4 de ratón en la región variable de la cadena pesada y la región variable de la cadena ligera.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015177081 | 2015-09-08 | ||
| PCT/JP2016/076102 WO2017043466A1 (ja) | 2015-09-08 | 2016-09-06 | 抗ＥｐｈＡ４抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018000652A2 true CO2018000652A2 (es) | 2018-06-20 |
Family
ID=58240770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0000652A CO2018000652A2 (es) | 2015-09-08 | 2018-01-24 | Anticuerpo anti-epha4 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10428140B2 (es) |
| EP (1) | EP3381941B1 (es) |
| JP (2) | JP6738814B2 (es) |
| KR (1) | KR20180041136A (es) |
| CN (2) | CN111320693B (es) |
| AR (1) | AR105938A1 (es) |
| AU (1) | AU2016319433A1 (es) |
| BR (1) | BR112018003494A2 (es) |
| CA (1) | CA2989993A1 (es) |
| CO (1) | CO2018000652A2 (es) |
| ES (1) | ES2846175T3 (es) |
| IL (2) | IL256519A (es) |
| MX (2) | MX377865B (es) |
| PE (1) | PE20181051A1 (es) |
| PH (1) | PH12018500290A1 (es) |
| RU (2) | RU2019128192A (es) |
| SG (1) | SG11201800127WA (es) |
| TW (1) | TW201716442A (es) |
| WO (1) | WO2017043466A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110769828A (zh) | 2017-05-12 | 2020-02-07 | 香港科技大学 | 作为epha4抑制剂的杂环化合物 |
| UY37757A (es) * | 2017-08-10 | 2018-11-30 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante |
| JPWO2020184350A1 (es) * | 2019-03-08 | 2020-09-17 | ||
| MA56466A (fr) * | 2019-07-01 | 2022-05-11 | Eisai R&D Man Co Ltd | Anticorps anti-epha4 |
| JPWO2022138708A1 (es) * | 2020-12-24 | 2022-06-30 | ||
| CN116710133A (zh) | 2020-12-24 | 2023-09-05 | 卫材R&D管理有限公司 | 肌萎缩侧索硬化的治疗用药物组合物 |
| TW202323286A (zh) * | 2021-11-11 | 2023-06-16 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| TW202330615A (zh) * | 2021-11-22 | 2023-08-01 | 中國醫藥大學 | Ｅｐｈｒｉｎ ａ型受體１０特異性抗體、表現其之嵌合抗原受體ｔ細胞及其應用 |
| WO2023122647A2 (en) * | 2021-12-22 | 2023-06-29 | The University Of Chicago | Methods for detecting or treating influenza infections |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334271B2 (ja) * | 2003-05-07 | 2009-09-30 | セレスター・レキシコ・サイエンシズ株式会社 | 抗体配列作成装置、抗体配列作成方法、プログラム、および、記録媒体 |
| KR20060034231A (ko) * | 2003-06-06 | 2006-04-21 | 메디뮨 인코포레이티드 | 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 |
| US7935793B2 (en) * | 2003-12-04 | 2011-05-03 | Abbott Biotherapeutics Corp. | Treatment of inflammatory bowel diseases with anti-IP-10 antibodies |
| EP1733047A2 (en) * | 2004-02-27 | 2006-12-20 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| JP2009531273A (ja) * | 2006-02-28 | 2009-09-03 | オンコセラピー・サイエンス株式会社 | 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法 |
| EP2166110B1 (en) | 2007-06-08 | 2012-02-22 | Eisai R&D Management Co., Ltd. | Screening method utilizing novel substrate epha4 for gamma-secretase |
| US7892769B2 (en) | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| JP2010285413A (ja) * | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| AU2010305374A1 (en) * | 2009-10-09 | 2012-05-03 | Sanofi | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| WO2012081502A1 (ja) | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
| WO2012147798A1 (ja) * | 2011-04-25 | 2012-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| EP3473271B1 (en) * | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
-
2016
- 2016-09-06 RU RU2019128192A patent/RU2019128192A/ru unknown
- 2016-09-06 BR BR112018003494-0A patent/BR112018003494A2/pt not_active Application Discontinuation
- 2016-09-06 CN CN202010179415.5A patent/CN111320693B/zh not_active Expired - Fee Related
- 2016-09-06 MX MX2018002164A patent/MX377865B/es unknown
- 2016-09-06 RU RU2018106456A patent/RU2719158C2/ru active
- 2016-09-06 US US15/753,611 patent/US10428140B2/en active Active
- 2016-09-06 AR ARP160102725A patent/AR105938A1/es unknown
- 2016-09-06 TW TW105128767A patent/TW201716442A/zh unknown
- 2016-09-06 WO PCT/JP2016/076102 patent/WO2017043466A1/ja not_active Ceased
- 2016-09-06 PE PE2017002724A patent/PE20181051A1/es not_active Application Discontinuation
- 2016-09-06 KR KR1020187004754A patent/KR20180041136A/ko not_active Withdrawn
- 2016-09-06 CN CN201680048438.4A patent/CN107922499B/zh not_active Expired - Fee Related
- 2016-09-06 ES ES16844327T patent/ES2846175T3/es active Active
- 2016-09-06 AU AU2016319433A patent/AU2016319433A1/en not_active Abandoned
- 2016-09-06 EP EP16844327.3A patent/EP3381941B1/en active Active
- 2016-09-06 SG SG11201800127WA patent/SG11201800127WA/en unknown
- 2016-09-06 CA CA2989993A patent/CA2989993A1/en not_active Abandoned
- 2016-09-06 JP JP2017539163A patent/JP6738814B2/ja active Active
-
2017
- 2017-12-24 IL IL256519A patent/IL256519A/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000652A patent/CO2018000652A2/es unknown
- 2018-02-08 PH PH12018500290A patent/PH12018500290A1/en unknown
- 2018-02-20 MX MX2020002406A patent/MX2020002406A/es unknown
-
2019
- 2019-08-23 JP JP2019152823A patent/JP6770153B2/ja not_active Expired - Fee Related
- 2019-08-25 IL IL26888919A patent/IL268889A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| EA201691488A1 (ru) | Молекулы антител против pd-1 и их применения | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| DK3408295T5 (da) | Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
| MX377710B (es) | Anticuerpos monoclonales contra bcma. | |
| EA201792055A1 (ru) | Антитела против cd48 и их конъюгаты | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| MX391989B (es) | Conjugados de amatoxina y anticuerpos. | |
| WO2016062722A8 (en) | Combination | |
| EA201790173A1 (ru) | Антитела, связывающие axl | |
| CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
| CN106456764A8 (zh) | 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
| NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
| EA201892368A1 (ru) | ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ | |
| EA201591709A1 (ru) | 5-бром-индирубины |